European Journal of Cancer
Volume 37, Issue 3 , Pages 300-321 , February 2001

Germ line mutations associated with breast cancer susceptibility

Received 5 May 2000 ,Revised 7 September 2000 ,Accepted 3 October 2000.

References 

  1. Adami HO, Hansen J, Jung B, Rimsten A. Characteristics of familial breast cancer in Sweden (absence of relation to age and unilateral and bilateral disease). Cancer. 1981;48:1688–1695
  2. Lubin JH, Burns PE, Blot WJ, et al.  Risk factors for breast cancer in women in North Alberta, Canada, as related to age at diagnosis. J. Natl. Cancer Inst. 1982;68:211–217
  3. Bain C, Speizer FE, Rosner B, Belanger C, Hennekens CH. Family history of breast cancer as a risk indicator for the disease. Am. J. Epidemiol. 1980;111:301–307
  4. Anderson DE. Some characteristics of familial breast cancer. Cancer. 1971;28:1500–1504
  5. Anderson DE. Genetic study of breast cancer (identification of a high risk group). Cancer. 1974;34:1090–1097
  6. Anderson DE. Breast cancer in families. Cancer. 1977;40:1855–1860
  7. Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH. Tumour variation in families with breast cancer. J. Am. Med. Assoc. 1972;222:1631–1635
  8. Williams WR, Anderson DE. Genetic epidemiology of breast cancer (segregation analysis of 200 Danish pedigrees). Genet. Epidemiol. 1984;1:7–20
  9. Newman B, Austin MA, Lee M, King M-C. Inheritance of breast cancer (evidence of autosomal dominant transmission in high risk families). Proc. Natl. Acad. Sci. USA. 1988;85:3044–3048
  10. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 1991;48:232–242
  11. Hall JM, Lee MK, Newman B, et al.  Linkage of early-onset breast cancer to chromosome 17q21. Science. 1990;250:1684–1689
  12. Narod SA, Feunteun J, Lynch HT, et al.  Familial breast–ovarian cancer locus on chromosome 17q12-23. Lancet. 1991;338:82–83
  13. Feunteun J, Narod SA, Lynch HT, et al.  A breast–ovarian cancer susceptibility gene maps to chromosome 17q21. Am. J. Hum. Genet. 1993;52:736–742
  14. Miki Y, Swenson J, Shattuck-Eidens D, et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  15. Wooster R, Neuhausen SL, Mangion J, et al.  Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–2091
  16. Schutte M, Rozenblum E, Moskaluk CA, et al.  An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12. Cancer Res. 1995;55:4570–4574
  17. Wooster R, Bignell G, Lancaster J, et al.  Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792
  18. Narod SA, Ford D, Devilee P, et al.  An evaluation of genetic heterogeneity in 145 breast–ovarian cancer families. Am. J. Hum. Genet. 1995;56:254–264
  19. Narod SA, Ford D, Devilee P, et al.  Genetic heterogeneity of breast–ovarian cancer revisited. Am. J. Hum. Genet. 1995;57:958–960
  20. Easton DF, Bishop DT, Ford D, Crockford GP. Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer (results from 214 families). Am. J. Hum. Genet. 1993;52:678–701
  21. Ford D, Easton DF, Stratton M, et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 1998;62:676–689
  22. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet. 1995;57:1457–1462
  23. Whittemore A, Gong G, Itnye J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer (results from three U.S. population case–control studies of ovarian cancer). Am. J. Hum. Genet. 1997;60:496–504
  24. Peto J, Collins N, Barfoot R, et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 1999;91:943–949
  25. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am. J. Hum. Genet. 1995;56:265–271
  26. Struewing J, Hartge P, Wacholder S, et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 1997;336:1401–1408
  27. Fodor FH, Weston A, Bleiweiss IJ, et al.  Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet. 1998;63:45–51
  28. Dorum A, Heimdal H, Hovig E, Inganas M, Moller P. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am. J. Hum. Genet. 1999;65:671–679
  29. Hopper JL, Southey MC, Dite GS, et al.  Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol. Biomarkers Prev. 1999;8:741–747
  30. Friedman LS, Szabo CI, Ostermeyer EA, et al.  Novel inherited mutations and variable expressibility of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am. J. Hum. Genet. 1995;57:1284–1297
  31. Devilee P. BRCA1 and BRCA2 testing (weighing the demand against the benefits). Am. J. Hum. Genet. 1999;64:943–948
  32. Foulkes WD. BRCA1 and BRCA2 (penetrating the clinical arena [commentary]). Lancet. 1998;352:1325–1326
  33. Easton DF, Steele L, Fields P, et al.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am. J. Hum. Genet. 1997;61:120–128
  34. Grompe M. The rapid detection of unknown mutations in nucleic acids. Nature Genet. 1993;5:111–117
  35. Greenman J, Mohammed S, Ellis D, et al.  Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. Genes Chrom. Cancer. 1998;21:244–249
  36. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA. 1989;86:2766–2770
  37. Hogervorst FBL, Cornelis RS, Bout M, et al.  Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genet. 1995;10:208–212
  38. Michaud J, Brody LC, Steel G, et al.  Strand-seperating conformational polymorphism analysis (efficacy of detection of point mutations in the human ornithine delta-aminotransferase gene). Genomics. 1992;13:389–394
  39. White MB, Carvalho M, Derse D, O'Brien SJ, Dean M. Detecting single base substitutions as heteroduplex polymorphisms. Genomics. 1992;12:301–306
  40. Roest PAM, Roberts RG, Sugino S, Van Ommen GJB, Dunnen JT. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum. Mol. Genet. 1993;2:1719–1721
  41. Shattuck-Eidens D, McClure M, Simard J, et al.  Collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. J. Am. Med. Assoc. 1995;273:535–541
  42. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum. Mutat. 1993;2:425–434
  43. Powell SM, Petersen GM, Krush AJ, et al.  Molecular diagnosis of familial adenomatous polyposis. N. Engl. J. Med. 1993;329:1982–1987
  44. Simard J, Tonin P, Durocher F, et al.  Common origin of the BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 1997;8:392–398
  45. Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Recurrent germ line BRCA1 mutations in extended African American families with early-onset breast cancer. Am. J. Hum. Genet. 1997;60:1233–1236
  46. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J. Med. Genet. 1996;33:814–819
  47. Shattuck-Eidens D, Oliphant A, McClure M, et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. J. Am. Med. Assoc. 1997;278:1242–1250
  48. Puget N, Torchard D, Serova-Sininikova OM, et al.  A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997;57:828–831
  49. Petrij-Bosch A, Peelen T, van Vliet M, et al.  BRCA1 genomic deletions are major founder effects in Dutch breast cancer patients. Nature Genet. 1997;7:341–345
  50. Tavtigian SV, Simard J, Rommens J, et al.  The complete BRCA2 gene and mutation in chromosome 13q-linked kindreds. Nature Genet. 1996;12:333–337
  51. Frank TS, Manley SA, Olopade OI, et al.  Sequence analysis of BRCA1 and BRCA2 (correlation of mutations with family history and ovarian cancer risk). J. Clin. Oncol. 1998;16:2417–2425
  52. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BAJ. Frequently occurring germ line mutation of the BRCA1 gene in ovarian cancer families from Russia. Am. J. Hum. Genet. 1997;60:1239–1242
  53. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res. 1995;55:3521–3524
  54. Lavy-Lehad E, Catane R, Eisenberg S, et al.  Recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel (frequency and differential penetrance in ovarian cancer and in breast–ovarian cancer families). Am. J. Hum. Genet. 1997;60:1059–1067
  55. Caligo MA, Ghimenti C, Cipollini G, et al.  BRCA1 germ line mutational spectrum in Italian families from Tuscany (a high frequency of novel mutations). Oncogene. 1996;13:1483–1488
  56. De Benedetti V, Radice P, Mondini P, et al.  Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by the protein truncation test. Oncogene. 1996;13:1353–1357
  57. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al.  Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet. 1997;60:1079–1084
  58. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet. 1996;13:117–119
  59. Struewing J, Abeliovich D, Peretz T, et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 1995;11:198–200
  60. Takahashi H, Behnakht K, McGovern PE, et al.  Mutation analysis of the BRCA1 gene in ovarian cancer. Cancer Res. 1995;55:2998–3002
  61. Tonin P, Serova O, Lenoir H, et al.  BRCA1 mutation in Ashkenazi Jewish women. Am. J. Hum. Genet. 1995;57:189
  62. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast–ovarian cancer families (a genetic study of 15 185delAG mutation kindreds). Am. J. Hum. Genet. 1996;58:1166–1176
  63. Neuhausen S, Gilewski T, Norton L, et al.  Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected with breast cancer. Nature Genet. 1996;13:126–128
  64. Oddoux C, Struewing J, Clayton C, et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jews is approximately 1 percent. Nature Genet. 1996;14:188–190
  65. Roa BB, Boyd AA, Richards KV, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet. 1996;14:185–187
  66. Wagner TMU, Moslinger RA, Muhr D, et al.  BRCA1- related breast cancer in Austrian breast and ovarian cancer families (specific BRCA1 mutations and pathological characteristics). Int. J. Cancer. 1998;7:354–360
  67. Tonin PN, Mes-Masson A-M, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin. Genet. 1999;55:218–224
  68. Anderson TI, Borresen A-L, Moller P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am. J. Hum. Genet. 1996;59:486–487
  69. Dorum A, Moller P, Kamsteeg EJ, et al.  A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Am. J. Hum. Genet. 1997;33:2390–2392
  70. Gorski B, Byrski T, Huzarski T, et al.  Founder mutations in the BRCA1 gene in Polish families with breast–ovarian cancer. Am. J. Hum. Genet. 2000;66:1963–1968
  71. Liede A, Cohen B, Black DM, et al.  Evidence of a founder BRCA1 mutation in Scotland. Br. J. Cancer. 2000;82:705–711
  72. Ford D, Easton DF, Bishop DF, Narod SF, Goldgar DE  the Breast Cancer Linkage Consortium . Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343:692–695
  73. Lin KM, Ternent CA, Adams DR, et al.  Colorectal cancer in hereditary breast cancer kindreds. Dis. Colon Rectum. 1999;42:1041–1045
  74. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germ line mutation carriers. Eur. J. Cancer. 1999;35:1248–1257
  75. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA. Germline BRCA1 mutations in selected men with prostate cancer. Am. J. Hum. Genet. 1996;58:881–885
  76. Lehrer S, Fodor F, Stock RG, et al.  Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br. J. Cancer. 1998;78:771–773
  77. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldson H. Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. BMJ. 1992;305:855–857
  78. Phelan CM, Lancaster JM, Tonin P, et al.  Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet. 1996;13:120–122
  79. Breast Cancer Linkage Consortium . Cancer risk in BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999;91:1310–1316
  80. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia. Am. J. Pathol. 2000;156:1767–1771
  81. Goggins M, Schuute M, Lu J, et al.  Germline BRCA2 gene mutations in patients in apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364
  82. Hruban RH, Peterson GM, Goggins M, et al.  Familial pancreatic cancer. Ann. Oncol. 1999;10(Suppl. 4):S69–S73
  83. Lal G, Liu G, Schmocker B, et al.  Inherited predisposition to pancreatic adenocarcinoma (role of family history and germ-line p16, BRCA1 and BRCA2 mutations). Cancer Res. 2000;60:409–416
  84. Nastiuk KL, Mansukhani M, Terry MB, et al.  Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate. 1999;40:172–177
  85. Wilkens EP, Freije D, Xu J, et al.  No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate. 1999;39:280–284
  86. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res. 2000;60:1371–1375
  87. Friedman LS, Ostermeyer EA, Szabo CI, et al.  Confirmation of BRCA1 by analysis of germ line mutations linked to breast and ovarian cancer in ten families. Nature Genet. 1994;8:399–404
  88. Vehmanen P, Friendman LS, Eerola H, et al.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families (evidence for additional susceptibility genes). Hum. Mol. Genet. 1997;13:2309–2315
  89. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M. Germline mutations of BRCA1 gene in breast and ovarian cancers provide evidence for a genotype–phenotype correlation. Nature Genet. 1995;11:428–433
  90. Serova O, Montagna M, Torchard D, et al.  A high incidence of BRCA1 mutations in breast–ovarian cancer families. Am. J. Hum. Genet. 1996;58:42–51
  91. Gayther SA, Mangion J, Russel P, et al.  Variation of risks of breast and ovarian cancer associated with different germ line mutations of the BRCA2 gene. Nature Genet. 1997;15:103–105
  92. Neuhausen SL, Godwin AK, Gershoni-Baruch R, et al.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families (results of an international study). Am. J. Hum. Genet. 1998;62:1381–1388
  93. Futreal PA, Liu Q, Shattuck-Eidens D, et al.  BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;226:120–122
  94. Lancaster JM, Wooster R, Mangion J, et al.  BRCA2 mutations in primary breast and ovarian cancers. Nature Genet. 1996;13:238–240
  95. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet. 1995;345:345
  96. Marcus JN, Watson P, Page DL, et al.  Hereditary breast cancer (pathology, prognosis and BRCA1 and BRCA2 gene linkage). Cancer. 1996;77:697–709
  97. Eisinger F, Soppa-Lyonnet D, Longy M, et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56:471–474
  98. Karp SE, Tonin PN, Begin LR, et al.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435–441
  99. Armes J, Matthew Egan AJ, Southey MC, et al.  The histological phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germ line mutations. Cancer. 1998;83:2335–2345
  100. Breast Cancer Linkage Consortium . Pathology of familial breast cancer (differences between breast cancer in carriers of BRCA1 and BRCA2 and sporadic cases). Lancet. 1997;349:1505–1510
  101. Lakhani SR, Jacquemier J, Sloane JP, et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998;90:1138–1145
  102. Iau PTC, Marafie M, Wenzyck P, et al.  Are medullary and atypical medullary cancers an indication for BRCA1 mutation screening. Breast. 1999;8:2
  103. Jacquemier J, Eisinger F, Guinebretiere J-M, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet. 1996;348:1098
  104. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1 [letter]. Lancet. 1996;348:408
  105. Marcus JN, Watson P, Page DL, et al.  BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res. Treat. 1997;47:275–277
  106. Agnarsson BA, Joasson JG, Bjornsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutaion associated with high grade breast cancer. Breast Cancer Res. Treat. 1998;47:121–127
  107. Fisher B, Constantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer (report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study). J. Natl. Cancer Inst. 1998;90:1371–1388
  108. Johannsson OT, Idvall I, Anderson C, et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer. 1997;33:362–371
  109. Verhoog LC, Brekelmans CTM, Seynaeve C, et al.  Survival and tumour characteristics of breast cancer patients with germ line mutations of BRCA1. Lancet. 1998;351:316–321
  110. Osin P, Crook T, Powles T, Peto J, Gusterson B. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet. 1998;351:1487
  111. Eisinger F, Nogues C, Guinebretiere JM, et al.  Novel indications for BRCA1 screening using individual clinical and morphological features. Int. J. Cancer. 1999;84:263–267
  112. Verhoog LC, Brekelmans CTM, Seynaeve C, et al.  Survival in hereditary breast cancer associated with germ line mutations of BRCA2. J. Clin. Oncol. 1999;17:3396–3402
  113. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1 or BRCA2 associated hereditary breast carcinoma in Japanese women. Cancer. 1999;95:2200–2205
  114. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet. 1993;341:184–185
  115. Porter DE, Cohen BB, Wallace MR, et al.  Breast cancer incidence, penetrance and survival in probably carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J. Surg. 1994;81:12–15
  116. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients (a population-based study from southern Sweden). J. Clin. Oncol. 1998;16:397–404
  117. Watson P, Marcus JN, Lynch HT. Prognosis of BRCA1 hereditary breast cancer. Lancet. 1998;51:304–305
  118. Poller DN, Hutchings CE, Galea M, et al.  P53 protein expression in human breast carcinoma (relationship to expression of epidermal growth factor, c-erbB-2 protein overexpression and oestrogen receptor). Br. J. Cancer. 1992;66:538–583
  119. Phillips K-A, Andrilus IL, Goodwin PJ. Breast carcinomas arising from carriers of mutations in BRCA1 and BRCA2 (are they prognostically different?). J. Clin. Oncol. 1999;17:653–663
  120. Chappuis PO, Rosenblatt J, Foulkes WD. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann. Oncol. 1999;10:1163–1170
  121. Foulkes WD, Wong N, Rozen F, Brunet J-S, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet. 1998;151:1359
  122. Foulkes WD, Chappuis PO, Wong N, et al.  Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann. Oncol. 2000;11:307–313
  123. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early onset breast cancer patients. Lancet. 1998;352:541
  124. Robson M, Gilewski T, Haas B, et al.  BRCA-associated breast cancer in young women. J. Clin. Oncol. 1998;16:1642–1649
  125. Swift M, Morrell D, Cromartie E, Chamberlain AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia on the United States. Am. J. Hum. Genet. 1986;39:573–583
  126. Swift M, Reitnauer PJ, Morrell D, Chase C. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 1987;316:1289–1294
  127. Borresen AL, Anderson TI, Tretli S, Heiberg A, Moller P. Breast cancer and other cancers in Nowegian families with ataxia-telangiectasia. Genes Chrom. Cancer. 1990;2:339–403
  128. Pippard EC, Hall AJ, Barker DJ, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 1988;48:2929–2932
  129. Easton DF. Cancer risks in AT heterozygotes. Int. J. Radiat. Biol. Phys. 1994;66(Suppl.):S177–S182
  130. Easton DF. The inherited component of cancer. Br. Med. Bull. 1994;50:226
  131. Gatti RA, Lange E, Rotman G, et al.  Genetic haplotyping of ataxia-telangiectasia families localises the major gene to an 850 kb region on chromosome 11q23.1. Int. J. Radiat. Biol. 1994;66:S57–S62
  132. Savitsky K, Bar-Shira A, Gilad S, et al.  A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;238:1749–1753
  133. Athma P, Rappaport R, Swift M. Molecular genotyping shows that at heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 1996;62:130–134
  134. Inskip HM, Kinlen LJ, Taylor AMR, Woods CG, Arlett CF. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer. 1999;79:1304–1307
  135. Stankovic T, Kidd AMJ, Sutcliffe A, et al.  ATM mutations and phenotypes in ataxia-telangiectasia famlies in the British Isles (expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer). Am. J. Hum. Genet. 1998;62:334–345
  136. Janin N, Andrieu N, Ossian K, et al.  Breast cancer in ataxia-telangiectasia (AT) heterozygotes (haplotype study in French AT families). Br. J. Cancer. 1999;80:1042–1045
  137. Fitzgerald MG, Bean JM, Hegde SR, et al.  Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genet. 1997;15:307–310
  138. Vorenchovsky I, Rasio D, Luo L, et al.  The ATM gene and susceptibility to breast cancer (analysis of 38 breast tumours reveals no evidence of mutation). Cancer. Res. 1996;15:2726–2732
  139. Vorechovsky I, Luo L, Lindbolm A, et al.  ATM mutations in cancer families. Cancer Res. 1996;56:4130–4133
  140. Meyn SM. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet. 1999;55:289–304
  141. Broeks A, Urbanus JHM, Floore AN, et al.  ATM-heterozyhous germ line mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 2000;66:494–500
  142. Bishop DT, Hopper H. AT-tributable risks?. Nature Genet. 1997;15:226
  143. Li F, Fraumeni JF. Soft tissue sarcomas, breast cancer and other neoplasms (a familial syndrome?). Ann. Intern. Med. 1969;71:747–751
  144. Li FP, Fraumeni JF. Prospective study of a family cancer syndrome. J. Am. Med. Assoc. 1982;247:2692–2694
  145. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J. Natl. Cancer Inst. 1987;79:1213–1220
  146. Malkin D, Li FP, Strong LC, et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science. 1990;250:1233–1238
  147. Sidransky D, Tokino T, Helzlsouer K, et al.  Inherited p53 mutations in breast cancer. Cancer Res. 1992;52:2984–2986
  148. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. P53 mutations in breast cancer. Cancer Res. 1992;52:5291–5298
  149. Bell DW, Varley JM, Szydlo TE, et al.  Heterozygoues germ line hCHK2 mutations in Li-Fraumeni Syndrome. Science. 1999;286:2528–2531
  150. Hirao A, Kong Y-Y, Matsuoka S, et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824–1827
  151. Lloyd II KM, Dennis M. Cowden's disease (a possible new symptom complex with multiple system involvement). Ann. Intern. Med. 1963;58:136–142
  152. Weary PE, Gorlin RJ, Gentry WC, Comer J, Greer KE. Multiple hamartoma syndrome (Cowden's disease). Arch. Dermatol. 1972;106:682–690
  153. Weinstock JV, Kawanishi H. Gastrointestinal polyposis with orocutaneous harmatomas (Cowden's disease). Gastroenterology. 1978;74:890–895
  154. Starink TM. Cowden's disease (multiple harmatoma and neoplasia syndrome). J. Am. Acad. Dermatol. 1983;8:686–696
  155. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease (a cutaneous marker of breast cancer). Cancer. 1978;41:2393–2398
  156. Li J, Yen C, Liaw D, et al.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947
  157. Li DM, Sun H. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res. 1997;57:2124–2129
  158. Longy M, Coulon V, Duboue B, et al.  Mutations at pTEN in patients with Bannayan–Riley–Ruvalcaba phenotype. J. Med. Genet. 1998;35:886–889
  159. Feilotter HE, Coulon V, McVeigh JL, et al.  Analysis of the 10q23 chromosomal region and the pTEN gene in human sporadic breast carcinoma. Br. J. Cancer. 1999;79:718–723
  160. Cairns P, Okami K, Halachmi S, et al.  Frequent inactivation of pTEN/MMAC1 in primary prostatic cancer. Cancer Res. 1997;57:4997–5000
  161. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–4738
  162. Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/pTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660–3663
  163. De Vivo I, Gertig DM, Nagase S, et al.  Novel germ line mutations in the pTEN tumour suppressor gene found in women with multiple cancers. J. Med. Genet. 2000;37:336–341
  164. German J. Bloom syndrome (a Mendellian prototype of somatic mutational disease). Medicine. 1993;72:393–406
  165. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity (LOH)/allelic imbalance in breast cancer. Cancer Res. 2000;60:3706–3712

PII: S0959-8049(00)00378-6

European Journal of Cancer
Volume 37, Issue 3 , Pages 300-321 , February 2001

Article Tools